Quarterly ResultJul 23, 2026, 06:11 AM
Thermo Fisher Q2 Revenue +10% to $11.99B; Adj. EPS +13% to $6.03
AI Summary
Thermo Fisher Scientific reported strong second-quarter 2026 financial results, with revenue growing 10% to $11.99 billion and adjusted EPS increasing 13% to $6.03. The company highlighted strengthening customer activity across its end markets and successful execution of its growth strategy, including new product launches and strategic collaborations. Capital deployment included the divestiture of its microbiology business and $1.0 billion in stock repurchases.
Key Highlights
- Second quarter revenue grew 10% to $11.99 billion, with 5% organic revenue growth.
- GAAP diluted EPS increased 9% to $4.68, and adjusted EPS grew 13% to $6.03.
- Repurchased $1.0 billion of company stock during the quarter.
- Life Sciences Solutions revenue was $2.815 billion, up from $2.499 billion in Q2 2025.
- Laboratory Products and Biopharma Services revenue reached $6.693 billion.
- Launched new Orbitrap platforms and the Applied Biosystems PowerFlex Thermal Cycler.
- Opened a flagship U.S. Bioprocess Design Center in Plainville, Massachusetts.
Price Impact
More from TMO